The CD4+ T cell response to HIV-1

Current Opinion in Immunology

Volumn 12, Issue 4, 2000, Pages 381-386

  Picker, Louis J ^a   Maino, Vernon C ^b  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^b BD Technologies   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD4 ANTIGEN;

CELLULAR IMMUNITY; HOST RESISTANCE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION CONTROL; LYMPHOCYTE FUNCTION; REVIEW; T LYMPHOCYTE;

EID: 0034051350     PISSN: 09527915     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0952-7915(00)00104-7     Document Type: Review

References (40)

1. Paul W.E. Can the immune response control HIV infection? Cell. 82:1995;177-182.
2. + T cell demographics and dynamics in lymphoid tissue Annu Rev Immunol. 17:1999;625-656.
3. Letvin N.L. Progress in the development of an HIV-1 vaccine Science. 280:1998;1875-1880.
4. Kanki P.J., Hamel D.J., Sankale J-L., Hsieh C-C., Thior I., Barin F., Woodcock S.A., Gueye-Ndiaye A., Zhang E., Montano M.et al. Human immunodeficiency virus type 1 subtypes differ in disease progression. J Infect Dis. 179:1999;68-73.
5. Mummidi S., Ahuja S.S., Gonzales E., Anderson S.A., Santiago E.N., Stephan K.T., Craig F.E., O'Connell P., Tryon V., Clark R.A.et al. Geneology of the CC5 locus and chemokine system gene variants associated with altered rates of HIV-1 disease progression. Nat Med. 4:1998;786-793.
6. + T cells.
7. + T cell responses were potent enough in vivo to force the specific selection of viral escape mutants but the fact that this occurred in all animals emphasizes that, even if initially successful, maintenance of long-term immune control over this virus will be an immense challenge.
8. + T cell effector activity in humans.
9. Hislop A.D., Good M.F., Mateo L., Gardner J., Gatei M.H., Daniel R.C.W., Meyers B.V., Lavin M.F., Suhrbier A. Vaccine-induced cytotoxic T lymphocytes protect against retroviral challenge Nat Med. 4:1998;1193-1196.
10. Parren P.W.H.I., Moore J.P., Burton D.R., Sattentau Q.J. The neutralizing antibody response to HIV-1: viral evasion and escape from humoral immunity AIDS. 13:1999;137-162.
11. Shibata R., Igarashi T., Haigwood N., Buckler-White A., Ogert R., Ross W., Willey R., Cho M.W., Martin M.A. Neutralizing antibody directed against the HIV-1 envelope glycoprotein can completely block HIV-1/SIV chimeric virus infections of macaque monkeys Nat Med. 5:1999;204-210.
12. Picker L.J., Siegelman M.H. Lymphoid tissues and organs. Paul W.E. Fundamental Immunology, edn 4. 1999;479-531 Lippincott-Raven Publishers, Philadelphia.
13. + T cell responses.
14. Rosenberg E.S., Walker B.D. HIV type 1-specific helper T cells: A critical host defense J AIDS Hum Retrovirol. 14:1998;143-147.
15. Valentine F.T., Palino A., Saito A., Holzman R.S. Lymphocyte-proliferative responses to HIV antigens as a potential measure of immunological reconstitution in HIV disease AIDS Res Human Retroviruses. 14:1998;S161-S166.
16. Musey L.K., Krieer J.N., Hughes J.P., Schacker T.W., Corey L., MeElrath M.J. Early and persistent human immunodeficiency virus type 1 (HIV-1)-specific T helper dysfunction in blood and lymph nodes following acute HIV-1 infection. J Infect Dis. 180:1999;278-284. This is a prospective study of a relatively large cohort of untreated subjects with acute/early HIV-1 infection, demonstrating that the vast majority of infected subjects failed to manifest HIV-1-specific lymphoproliferation over the first two years of their infection.
17. + T cell responses associated with control of viremia Science. 278:1997;1447-1450.
18. Shearer G.M. HIV-induced immunopathogenesis Immunity. 9:1998;587-593.
19. + T cell responses in vivo.
20. + T cell frequencies by flow cytometry: evidence for a novel, antigen-specific homeostatic mechanism in HIV-associated immunodeficiency J Clin Invest. 99:1997;1739-1750.
21. + memory T cells display broad heterogeneity in their activation threshold for cytokine synthesis J Immunol. 161:1998;5284-5295.
22. + count; sixth, they are reduced with sustained, effective viral suppression by HAART (see text).
23. Mackall C.L., Gress R.E. Pathways of T-cell regeneration in mice and humans: implications for bone marrow transplantation and immunotherapy Immunol Rev. 157:1997;61-72.
24. ••] remains to be precisely determined.
25. + T cell responses in subjects after effective HAART could be rapidly reconstituted by vaccination with Remune™, a vaccine preparation of inactivated, gp120-depleted HIV-1 virions.
26. Pontesilli O., Kerkhof-Garde S., Notermans D.W., Foudraine N.A., Roos M.T.L., Klein M.R., Danner S.A., Lange J.M.A., Miedema F. Functional T cell reconstitution and human immunodeficiency virus-1-specific cell-mediated immunity during highly active antiretroviral therapy J Infect Dis. 180:1999;76-86.
27. Rinaldo C.R. Jr., Liebmann J.M., Huang X-L., Fan Z., Al-Shboul Q., McMahon D.K., Day R.D., Riddler S.A., Mellors J.W. Prolonged suppression of human immunodeficiency virus type 1 (HIV-1) viremia in persons with advanced disease results in enhancement of CD4 T cell reactivity to microbial antigens but not to HIV-1 antigens. J Infect Dis. 179:1999;329-336.
28. Connick E., Lederman M.M., Kotzin B.L., Spritzler J., Kuritzkes D.R., St Clair M., Sevin A.D., Fox L., Chiozzi M.H., Leonard J.M.et al. Immune reconstitution in the first year of potent antiretroviral therapy and its relationship to virologic response. J Infect Dis. 181:2000;358-363.
29. Malhotra U., Berrey M.M., Huang Y., Markee J., Brown D.J., Ap S., Musey L., Schacker T., Corey L., McElrath M.J. Effect of combination antiretroviral therapy on T cell immunity in acute human immunodeficiency virus type 1 infection J Infect Dis. 181:2000;121-131.
30. Lori F., Jessen H., Lieberman J., Finzi D., Rosenberg E., Tinelli C., Walker B., Siliciano R.F., Lisziewicz J. Treatment of human immunodeficiency virus infection with Hydroxyurea, Didanosine, and a protease inhibitor before seroconversion is associated with normalized immune parameters and limited viral reservoir J Infect Dis. 180:1999;1827-1832.
31. + cytotoxic T-cell responses during chronic viral infection J Virol. 68:1994;8056-8063.
32. + T-cell-deficient mice J Virol. 68:1994;4700-4704.
33. von Herrath M.G., Yokoyama M., Dockter J., Oldstone M.B.A., Whitton J.L. CD4-deficient mice have reduced levels of memory cytotoxic T lymphocytes after immunization and show diminished resistance to subsequent virus challenge J Virol. 70:1996;1072-1079.
34. + T cell mediated control of a gamma-herpes virus in B cell deficient mice is mediated by IFN-gamma Proc Natl Acad Sci USA. 96:1999;5135-5140.
35. Dittmer U., Brooks D.M., Hasenkrug K.J. Requirement for multiple lymphocyte subsets in protection by a live attenuated vaccine against retroviral infection Nat Med. 5:1999;189-193.
36. Zajac A.J., Blattman J.N., Murali-Krishna K., Sourdive D.J.D., Suresh M., Altman J.D., Ahmed R. Viral immune evasion due to persistence of activated T cells without effector function J Exp Med. 188:1998;2205-2213.
37. Riddell S.R., Greenberg P.D. T cell therapy of human CMV and EBV infection in immunocompromised hosts Rev Med Virol. 7:1997;181-192.
38. + cells may play a role in viral resistance.
39. + proliferative responses.
40. + T cells responses in such animals, as compared with animals infected with pathogenic strains.